ContextVision Financial Leverage
The Financial Leverage (Equity Multiplier) of ContextVision (CONTX.OL) as of Jul 29, 2026 is 1.35. In the previous year, Financial Leverage (Equity Multiplier) was 1.38 — a change of -1.97% (lower).
Get this data via API
Financial Data API
Financial Leverage
1.35
YoY
-1.97%
Last updated:
Financial Leverage (Equity Multiplier) of ContextVision is 2026 1.35 . Financial Leverage (Equity Multiplier) of ContextVision was 2025 1.38 . It decreases by -1.97% lower compared to the previous year.
Access this data via the Eulerpool API
ContextVision Stock analysis
What does ContextVision do? ContextVision AB is a global provider of medical imaging software, specializing in the development and provision of advanced software for use in radiology, mammography, ultrasound, and digital pathology. They offer a wide range of products, including VOCAL for three-dimensional analysis of volume data, GOPView® US for real-time optimization of ultrasound images, and INIFY Prostate for the analysis of tissue samples in prostate cancer. The company is committed to continuous improvement and innovation, working closely with customers and partners to exchange ideas and incorporate innovative technologies in modern medicine. ContextVision is one of the most popular companies on Eulerpool.
Frequently Asked Questions about ContextVision stock
Financial Leverage (Equity Multiplier) of ContextVision is 1.35 in 2026.
Access this data via the Eulerpool API
Leverage — ContextVision
All Key Metrics — ContextVision
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth